Lecanamab: A Game-Changing Drug for Alzheimer's Disease

Today's approval of Lecanamab is a step forward for a disease that has been largely untreatable. In Alzheimer's patients, amyloid proteins form plaques in the brain which interrupt normal communication between nerve cells leading to cognitive decline. Researchers say it's not a cure and cannot restore memories. Still, for patients like Susie Mitchell, the drug is providing something that's hard to quantify.